FDA approves bemotrizinol after decades-long wait
The US Food and Drug Administration approved bemotrizinol, the first new sunscreen active ingredient authorized in the United States in a quarter-century. The ingredient, already used in sunscreens across Europe and Asia for years, offers broader UV protection and better stability than existing options. Dermatologists welcomed the approval, noting that it gives American consumers access to advanced sun protection technology that has been available elsewhere for decades.
Vaccine-autism study retracted after CDC review
A controversial study that had been included in the CDC's hepatitis B birth vaccination review was retracted after researchers found methodological flaws. The retraction is the latest chapter in the long-debunked link between vaccines and autism, which continues to fuel vaccine hesitancy despite overwhelming scientific evidence to the contrary. Public health officials hope the retraction will help counter misinformation.
GLP-1 drugs show muscle-preserving benefits
New research on GLP-1 weight-loss medications, including survodutide, suggests these drugs may reduce harmful visceral fat while preserving muscle mass — an advantage over other weight loss approaches. The findings come amid growing use of GLP-1 drugs for weight management and increasing scrutiny of their side effects. The FDA also issued a safety alert about kidney risks associated with the weight-loss drug orlistat, underscoring the need for medical supervision with these medications.